Relationships of CRP and P wave dispersion with atrial fibrillation in hypertensive subjects

American Journal of Hypertension

Volumn 23, Issue 2, 2010, Pages 202-207

  Tsioufis, Costas ^a   Syrseloudis, Dimitris ^a   Hatziyianni, Awalia ^a   Tzamou, Vanessa ^a   Andrikou, Ioannis ^a   Tolis, Panaglotis ^a   Toutouzas, Kostas ^a   Michaelidis, Andreas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Atrial fibrillation; Blood pressure; CRP; Hypertension; Inflammation; P wave dispersion

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; P WAVE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE;

AGED; ATRIAL FIBRILLATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PULSATILE FLOW;

EID: 75549087584     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.231     Document Type: Article

References (27)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952.
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med 2002; 113:359-364.
4. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-1022.
5. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82:2N-9N.
6. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98:476-484.
7. Lévy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin Electrophysiol 1997; 20:2670-2674.
8. Tai CT, Chen SA, Tzeng JW, Kuo BI, Ding YA, Chang MS, Shyu LY. Prolonged fractionation of paced right atrial electrograms in patients with atrial flutter and fibrillation. J Am Coll Cardiol 2001; 37:1651-1657.
9. Dilaveris PE, Gialafos EJ, Chrissos D, Andrikopoulos GK, Richter DJ, Lazaki E, Gialafos JE. Detection of hypertensive patients at risk for paroxysmal atrial fibrillation during sinus rhythm by computer-assisted P wave analysis. J Hypertens 1999; 17:1463-1470.
10. Aytemir K, Ozer N, Atalar E, Sade E, Aksöyek S, Ovünç K, Oto A, Ozmen F, Kes S. P wave dispersion on 12-lead electrocardiography in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2000; 23:1109-1112.
11. Tsioufis C, Syrseloudis D, Dimitriadis K, Thomopoulos C, Tsiachris D, Pavlidis P, Selima M, Kallikazaros I, Stefanadis C. Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J Hum Hypertens 2008; 22:501-508.
12. Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I, Stefanadis C, Kallikazaros I. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol 2005; 96:252-256.
13. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010.
14. Siu CW, Lau C P, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92:1343-1345.
15. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92:1379-1383.
16. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, Chlouverakis GI, Vardas PE. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008; 94:200-204.
17. Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D, Tseng ZH, Badhwar N, Lee BK, Lee RJ, Scheinman MM, Olgin JE. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm 2008; 5:215-221.
18. Tsioufis C, Stefanadis C, Goumas G, Pitsavos C, Toutouzas P. Relation of ambulatory blood pressure load with left ventricular geometry in untreated patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:677-682.
19. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ; American Society of Echocardiography. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17:1086-1119.
20. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann S P, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy R P, Vinicor F; Centers for Disease Control and Prevention. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
21. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886-2891.
22. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152:217-222.
23. Bruins P, te Velthuis H, Yazdanbakhsh A P, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96: 3542-3548.
24. Lee YA, Liang CS, Lee MA, Lindpaintner K. Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog. Proc Natl Acad Sci USA 1996; 93:11035-11040.
25. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, Toutouzas P, Stefanadis C, Kallikazaros I. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96:946-951. (Pubitemid 41362518)
26. Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, Gialafos JE, Toutouzas PK. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998; 135:733-738.
27. Yamada T, Fukunami M, Shimonagata T, Kumagai K, Sanada S, Ogita H, Asano Y, Hori M, Hoki N. Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation. Eur Heart J 1999; 20:211-220.